RYR1 and neoplasm: In the current study, CC patients with WDFY4 mutation have much higher WDFY4 expression than those with wildtype WDFY4 in TCGA cohort (Fig. S8a), suggesting that WDFY4 mutation may promote anti-tumor immune response and the consequent better prognosis of CC through increasing the expression of WDFY4. Another core gene, RYR1, can also lead to the increased killing effect of NK cells and changes in anti-inflammatory cytokines once mutated.